Relmacabtagene autoleucel

DB18979InvestigationalCell transplant therapies

Relmacabtagene autoleucel: Overview.

Mechanism
Curator reviewed
Also known as
AUTOLOGOUS CD4+ AND CD8+ T CELLS, ENRICHED FROM PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) TRANSDUCED WITH A NONREPLICATIVE SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR ENCODING A CHIMERIC ANTIGEN RECEPTOR (CAR) CONSISTING OF THE HUMAN CD19-SPECIFIC SCFV · Carteyva · relma-cel

Resolves to

Compound
UNIIK5CXA4X5U8
Targets
P15391CD19

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
19Clinical trialsPhase, status and sponsor resolved per trial
Sign in
5+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Relmacabtagene autoleucel, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In